This program, initiated in 2019 after receiving accreditation from the Ministry of Health, uses genetically modified T-lymphocytes from the patient themselves to combat cancer cells. The center, affiliated with the Department of Health of the Government of the Canary Islands, thus consolidates itself as a benchmark in the application of complex hematological treatments in the archipelago.
CAR-T therapy involves extracting the patient's T-lymphocytes, modifying them in a laboratory to attack tumor cells, and reintroducing them via transfusion. The goal is for the immune system to recognize and eliminate cancer cells, being indicated for patients with few therapeutic alternatives.
The development of this CAR-T activity at Doctor Negrín Hospital involves the coordination of professionals from Hematology, Hospital Pharmacy, Neurology, Intensive Care Medicine, and Nursing, in addition to the center's diagnostic laboratory.
Recently, the Hematology department has expanded its services with the treatment of myeloma in the second line and maintains its role as a reference for allogeneic hematopoietic stem cell transplantation. The activity is complemented by research and training aimed at improving care for patients with hematological diseases.
A multidisciplinary CAR-T committee, including hematologists and oncologists from other Canary Islands health centers, periodically reviews new cases and the progress of patients undergoing treatment. This coordination facilitates the joint assessment of candidates for the therapy within the public health system of the Canary Islands.
